For example, its large acquisition of Celgene provided it with ... BMY)’s recent acquisitions i.e., oncology firms Mirati and RayzeBio and neurology firm Karuna, continue to strengthen the ...

Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and patent ...

Augtyro came from BMS’s $4.1 billion acquisition of Turning Point Therapeutics ... development move in the hot field of ADCs. Acquiring Mirati Therapeutics brings Bristol Myers Squibb Krazati ...

The drugmaker sees additional growth opportunities in ophthalmology and neuromuscular disorders, Chief Medical Officer Tadaaki Taniguchi said.

Seigerman added that Mirati has expressed interest to commercialise on its own, but "we think an acquisition by a larger biopharma name with experience in commercialising oncology assets could be ...

To list the 10 Best Wide Moat Stocks to Invest In, we scanned through VanEck Morningstar Wide Moat ETF and some online ...

Mirati, meanwhile, said that Krazati brought in just $36 million in the first nine months of 2023, ahead of BMS’ acquisition, and BMS recorded $21 million in sales in the first quarter of 2024.

Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.

If the merger/acquisition does go through, the combined companies would become the third-largest automaker in the world behind Toyota and the Volkswagen Group. Last month during a media roundtable ...